IP Library Granted Patent US 12,510,690
Granted Patent B2
US 12,510,690 · App. 18/103,788 · Granted Dec 30, 2025

Ophthalmic devices

Inventors: Feng-Yang Shih (Rochester, NY); Mohammad Vatankhah Varnosfaderani (Rochester, NY); Alok Kumar Awasthi, Jr. (Pittsford, NY)
Assignee: BAUSCH + LOMB IRELAND LIMITED
G02B1/043A61L27/18C08G73/0233
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,510,690
App. No.
18/103,788
Granted
Dec 30, 2025
Kind
B2
Abstract

An ophthalmic device which is a polymerization product of a monomeric mixture includes (a) one or more cationic initiators comprising one or more polymerizable groups; and (b) one or more alkyl-substituted oxazolines.

Claims (30)

1 . An ophthalmic device which is a polymerization product of a monomeric mixture comprising:

(a) one or more cationic initiators comprising one or more polymerizable groups; and

(b) one or more alkyl-substituted oxazolines.

2 . The ophthalmic device according to claim 1 , wherein the one or more cationic initiators comprising one or more polymerizable groups comprise one or more sulfonate cationic initiators comprising one or more polymerizable groups.

3 . The ophthalmic device according to claim 1 , wherein the one or more cationic initiators comprising one or more polymerizable groups comprise one or more of a substituted or unsubstituted alkyl- and aryl-containing sulfonate cationic initiator comprising one or more polymerizable groups or a fluorinated substituted or unsubstituted alkyl- and aryl-containing sulfonate cationic initiator comprising one or more polymerizable groups.

4 . The ophthalmic device according to claim 1 , wherein the one or more cationic initiators comprising one or more polymerizable groups comprise one or more sulfonate cationic initiators selected from the group consisting of tosylate, nosylate, mesylate, and triflate, each comprising one or more polymerizable groups.

5 . The ophthalmic device according to claim 1 , wherein the one or more polymerizable groups of the one or more cationic initiators comprise one or more of a (meth)acrylate end group, a vinyl end group, and an acrylamide end group.

6 . The ophthalmic device according to claim 1 , wherein the one or more cationic initiators comprising one or more polymerizable groups are derived from a reaction product of a hydroxyl-containing (meth)acrylate and a compound of the formula R—SO 2 —X where R is a hydrocarbon radical or moiety and X is a halogen.

7 . The ophthalmic device according to claim 1 , wherein the polymerization product comprises a brush polymeric network comprising poly(2-alkyloxazoline) repeating units in the polymer backbone represented by the formula:

where R is an alkyl group of 1 to 12 carbon atoms.

8 . The ophthalmic device according to claim 7 , wherein the brush polymeric network comprises from about 3 to about 150 repeating units of the poly(2-alkyloxazoline) in the polymer backbone.

9 . The ophthalmic device according to claim 1 , wherein the monomeric mixture comprises:

about 0.1 wt. % to about 30 wt. %, based on the total weight of the monomeric mixture, of the one or more cationic initiators; and

about 10 wt. % to about 80 wt. %, based on the total weight of the monomeric mixture, of the one or more alkyl-substituted oxazolines.

10 . The ophthalmic device according to claim 1 , wherein the monomeric mixture further comprises one or more crosslinking agents.

11 . The ophthalmic device according to claim 10 , wherein the one or more crosslinking agents comprise an ethylenically unsaturated polymerizable alkoxylated polymer.

12 . The ophthalmic device according to claim 11 , wherein the one or more ethylenically unsaturated polymerizable alkoxylated polymers comprise one or more polymerizable polyethylene glycols having a number average molecular weight of 100 to about 1000.

13 . The ophthalmic device according to claim 10 , wherein the one or more crosslinking agents comprise one or more end functionalized poloxamers.

14 . The ophthalmic device according to claim 10 , wherein the monomeric mixture comprises about 0.5 wt. % to about 30 wt. %, based on the total weight of the monomeric mixture, of the one or more crosslinking agents.

15 . The ophthalmic device according to claim 1 , wherein the monomeric mixture further comprises one or more hydrophilic monomers selected from the group consisting of an acrylamide and a vinyl lactam.

16 . The ophthalmic device according to claim 15 , wherein the monomeric mixture comprises about 10 wt. % to about 80 wt. %, based on the total weight of the monomeric mixture, of the one or more hydrophilic monomers.

17 . The ophthalmic device according to claim 1 , wherein the monomeric mixture further comprises one or more protected hydrophilic monomers selected from the group consisting of a protected (meth)acrylic acid and a protected hydroxyl-containing-(meth)acrylate.

18 . The ophthalmic device according to claim 1 , wherein the monomeric mixture further comprises one or more ultraviolet blockers.

19 . The ophthalmic device according to claim 1 , which is one or more of a contact lens, an intraocular lens and a corneal implant.

20 . A method for making an ophthalmic device, comprising:

(a) providing an ophthalmic device-forming monomeric mixture comprising:

(i) one or more cationic initiators comprising one or more polymerizable groups; and

(ii) one or more alkyl-substituted oxazolines;

(b) subjecting the mixture to polymerization conditions to provide a polymerized ophthalmic device; and

(c) hydrating the polymerized ophthalmic device.

Assignments (5)
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (063878/0110) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072486/0733 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
SECURITY INTEREST Recorded Feb 12, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 066552/0041 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 6, 2023
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 063878/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2023
From: SHIH, FENG-YANG; VATANKHAH VARNOSFADERANI, MOHAMMAD; AWASTHI, ALOK KUMAR
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 062560/0641 →
Continuity (2)
Provisional Application 63313413 · Feb 24, 2022
Related Publication 20230266505A1 · Aug 24, 2023
References Cited (34)
US 3408429A · Wichterle · 1968 [cited by applicant]
US 3660545A · Wichterle · 1972 [cited by applicant]
US 4113224A · Clark et al. · 1978 [cited by applicant]
US 4197266A · Clark et al. · 1980 [cited by applicant]
US 4327203A · Deichert et al. · 1982 [cited by applicant]
US 4355147A · Deichert et al. · 1982 [cited by applicant]
US 4555732A · Tuhro · 1985 [cited by applicant]
US 4910277A · Bambury et al. · 1990 [cited by applicant]
US 5070215A · Bambury et al. · 1991 [cited by applicant]
US 5270418A · Kunzler et al. · 1993 [cited by applicant]
US 5271875A · Appleton et al. · 1993 [cited by applicant]
US 5789487A · Matyjaszewski · 1998 [cited by examiner]
US 5807937A · Matyjaszewski · 1998 [cited by examiner]
US 6447920B1 · Chabrecek · 2002 [cited by examiner]
US 6517933B1 · Soane et al. · 2003 [cited by applicant]
US 6790809B2 · Suzuki · 2004 [cited by examiner]
US 9309357B2 · Awasthi et al. · 2016 [cited by applicant]
US 20010044482A1 · Hu · 2001 [cited by examiner]
US 20030044468A1 · Cellesi et al. · 2003 [cited by applicant]
US 20080151180A1 · Vanderbilt · 2008 [cited by examiner]
US 20090218705A1 · Patterson · 2009 [cited by examiner]
US 20120283381A1 · Tamiya · 2012 [cited by examiner]
US 20130317131A1 · Scales · 2013 [cited by examiner]
US 20200270371A1 · Hsieh · 2020 [cited by examiner]
GB 2339202A · 2020 [cited by applicant]
WO PCTEP2023054523A1 · 2023 [cited by applicant]
Edmondo M. Benetti et al., “Using Polymers to Impart Lubricity and Biopassivity to Surfaces: Are These Properties Linked?”, Helv. Chim. Acta., 2019, 11 pages, vol. 102, No. 5. [cited by applicant]
Giulia Morgese et al., “Mixing Poly(ethylene glycol) and Poly(2-alkyl-2-oxazoline)s Enhances Hydration and Viscoelasticity of Polymer Brushes and Determines Their Nanotribological and Antifouling Properties”, ACS Appl. … [cited by applicant]
Giulia Morgese et al., “Hairy and Slippery Polyoxazoline-Based Copolymers on Model and Cartilage Surfaces”, Biomacromolecules, 2018, pp. 680-690, 19. [cited by applicant]
Wenqing Yan et al., “Bioinert and Lubricious Surfaces by Macromolecular Design”, Langmuir, 2019, pp. 13521-13535, 35. [cited by applicant]
Giulia Morgese et al., “Nanoassemblies of Tissue-Reactive, Polyoxazoline Graft-Copolymers Restore the Lubrication Properties of Degraded Cartilage,” ACS Nano., 2017, pp. 2794-2804, 11. [cited by applicant]
Richard Hoogenboom et al., “Poly(2-oxazoline)s: A Polymer Class with Numerous Potential Applications”, Angew. Chem. Int. Ed., 2009, pp. 7978-7994, 48. [cited by applicant]
Mirko Einzmann et al., “Novel Functional Initiators for Oxazoline Polymerization”, Journal of Polymer Science: Part A: Polymer Chemistry, 2001, pp. 2821-2831, 39. [cited by applicant]
Mathias Glassner et al., “Poly(2-oxazoline)s: A comprehensive overview of polymer structures and their physical properties”, Polym Int., 2018, pp. 32-45, 67. [cited by applicant]